publication venue for
- Efficacy and safety of rivaroxaban versus placebo after lower extremity bypass surgery: A post hoc analysis of a “CASPAR like” outcome from VOYAGER PAD. 45:1143-1146. 2022
-
Contemporary use of
guideline‐based higher potencyP2Y12 receptor inhibitor therapy in patients withmoderate‐to‐high risknon‐ST‐segment elevation myocardial infarction: Results from the CanadianACS reflectiveII cross‐sectional study. 44:839-847. 2021 -
Association of psychosocial factors with
all‐cause hospitalizations in patients with atrial fibrillation. 44:51-57. 2021 -
Efficacy and safety of dronedarone by atrial fibrillation history duration: Insights from the
ATHENA study. 43:1469-1477. 2020 -
Impact of gender: Rivaroxaban for patients with atrial fibrillation in the
XANTUS real‐world prospective study. 43:1405-1413. 2020 - Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study. 42:498-505. 2019
- Stroke prevention in patients from Latin American countries with non‐valvular atrial fibrillation: Insights from the GARFIELD‐AF registry. 42:553-560. 2019
- Underpowered observational studies create confusion regarding clinical impact of surgical interventions. 42:416-416. 2019
- Design and rationale of the atrial fibrillation occurring transiently with stress (AFOTS) follow‐up cohort study. 41:1273-1280. 2018
- Stroke‐prevention strategies in North American patients with atrial fibrillation: The GLORIA‐AF registry program. 41:744-751. 2018
- Marital status and outcomes after myocardial infarction: Observations from the Canadian Observational Antiplatelet Study (COAPT). 41:285-292. 2018
- Impact of Switching From a Vitamin K Antagonist to Rivaroxaban on Satisfaction With Anticoagulation Therapy: The XANTUS‐ACTS Substudy. 39:565-569. 2016
- Cardioversion of Atrial Fibrillation in ENGAGE AF-TIMI 48. 39:345-346. 2016
- Culprit Vessel Only vs Immediate Complete Revascularization in Patients With Acute ST-Segment Elevation Myocardial Infarction: Systematic Review and Meta-Analysis. 37:765-772. 2014
- Efficacy and Safety of Dronedarone in Patients Previously Treated With Other Antiarrhythmic Agents. 37:717-724. 2014
- Pharmacogenetics in Cardiovascular Disease: The Challenge of Moving From Promise to Realization. 37:48-56. 2014
- Effects of Dronedarone Started Rapidly After Amiodarone Discontinuation. 36:88-95. 2013
- Letter to the Editor. 35:646-646. 2012
- QT Prolongation Is an Independent Predictor of Mortality in End-Stage Renal Disease. 33:361-366. 2010
- Symptom Presentation in Patients Hospitalized with Acute Heart Failure. 33:E73-E80. 2010
- Serial Analyses of C-Reactive Protein and Myeloperoxidase in Acute Coronary Syndrome. 32:E58-E62. 2009
- B-type Natruiretic Peptide Levels Stratify the Risk for Arrhythmia Among Implantable Cardioverter Defibrillator Patients. 31:586-589. 2008
- Progress in Clinical Trials. 31:89-94. 2008
- Bleeding Complications in Acute Coronary Syndromes and Percutaneous Coronary Intervention: Predictors, Prognostic Significance, and Paradigms for Reducing Risk. 30:II24-II34. 2007
- Bleeding complications in acute coronary syndromes and percutaneous coronary intervention: predictors, prognostic significance, and paradigms for reducing risk.. 30:II24-II34. 2007
- Association of statin therapy and the risk of atrial fibrillation in patients with a permanent pacemaker. 29:249-252. 2006
- Giant left atrium. 29:179-179. 2006
- Prognostic impact of demographic factors and clinical features on the mode of death in high-risk patients after myocardial infarction - A combined analysis from multicenter trials. 28:471-478. 2005
- Deciphering the sinus tachycardias - Reply. 28:401-401. 2005
- Can we differentiate the low-molecular-weight heparins?. 23:4-7. 2000
- Management strategies in unstable coronary artery disease-Current problems and future directions. 22:551-553. 1999
- Management Strategies for a Better Outcome in Unstable Coronary Artery Disease. 21:314-322. 1998
- Patterns of angiotensin-converting enzyme inhibitor prescriptions, educational interventions, and outcomes among hospitalized patients with heart failure. 21:261-268. 1998
- Clinical experience in protecting the failing heart.. 16:II25-II29. 1993
- The effect of treatment on survival in congestive heart failure. 15:323-329. 1992
- ANISTREPLASE (APSAC) - A CLINICAL INVESTIGATORS UPDATE - A SYMPOSIUM - DISCUSSION .1.. 13:V27-V32. 1990
- ANISTREPLASE (APSAC) - A CLINICAL INVESTIGATORS UPDATE - A SYMPOSIUM - DISCUSSION .2.. 13:V67-V72. 1990
- Expanding indications for the use of thrombolytic agents in acute myocardial infarction. 13:53-61. 1990
- Clinical experience in protecting the failing heart 1993